VolitionRx (NYSE:VNRX) Announces Quarterly Earnings Results

VolitionRx (NYSE:VNRXGet Free Report) posted its quarterly earnings data on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, Zacks reports. VolitionRx had a negative net margin of 4,557.29% and a negative return on equity of 7,185.73%. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.50 million.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.75 on Wednesday. VolitionRx has a fifty-two week low of $0.55 and a fifty-two week high of $2.10. The company has a quick ratio of 0.69, a current ratio of 0.69 and a debt-to-equity ratio of 0.56. The business has a fifty day moving average price of $1.00 and a two-hundred day moving average price of $0.87.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Vanguard Group Inc. raised its position in VolitionRx Limited (NYSE:VNRXFree Report) by 16.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 629,639 shares of the company’s stock after buying an additional 87,195 shares during the quarter. Vanguard Group Inc. owned about 0.80% of VolitionRx worth $451,000 at the end of the most recent quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.

Read More

Earnings History for VolitionRx (NYSE:VNRX)

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.